| 1.65 -0.1 (-5.71%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.03  |
1-year : | 3.73 |
| Resists | First : | 2.6 |
Second : | 3.2 |
| Pivot price | 2.14 |
|||
| Supports | First : | 1.62 |
Second : | 1.35 |
| MAs | MA(5) : | 1.77 |
MA(20) : | 2.21 |
| MA(100) : | 3.35 |
MA(250) : | 4.51 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 7.6 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 9.5 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XCUR ] has closed above bottom band by 16.5%. Bollinger Bands are 57.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.6 - 1.61 | 1.61 - 1.63 |
| Close: | 1.63 - 1.65 | 1.65 - 1.67 |
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Mon, 13 Jul 2026
How Exicure Inc. (XCUR) Affects Rotational Strategy Timing - Stock Traders Daily
Tue, 07 Jul 2026
Exicure stock holds its line. Company context stays front and center. - ad-hoc-news.de
Sat, 04 Jul 2026
Enterprise value to EBITDA forward of Exicure, Inc. – NASDAQ:XCUR - TradingView
Tue, 30 Jun 2026
New directors join Exicure (NASDAQ: XCUR) board as compensation committee forms - Stock Titan
Tue, 30 Jun 2026
Exicure expands board to 6, names 2 new directors - Stock Titan
Fri, 26 Jun 2026
Exicure, Inc. Actuals & Estimates (NASDAQ:XCUR) - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 32.8 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -145.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.06 |
| PEG Ratio | 0 |
| Price to Book value | 4.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|